Pazopanib in the treatment of advanced renal cell carcinoma

Therapeutic Advances in Urology

Volumn 8, Issue 1, 2016, Pages 61-69

  Cella, David ^a   Beaumont, Jennifer L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

clinical experience; health related quality of life; metastatic renal cell carcinoma; patient reported outcomes; pazopanib; tyrosine kinase inhibitors

Indexed keywords

PAZOPANIB; SUNITINIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY METASTASIS; MULTICENTER STUDY (TOPIC); NATURALISTIC INQUIRY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84954055043     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287215614236     Document Type: Review

References (40)

1. Beaumont J. Diaz J. Deen K. McCann L. Powles T. Hackshaw M. (2014) Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN). J Clin Oncol 32(Suppl. 5): abstr. 4581.
2. Cella D. Eton D. Lai J. Peterman A. Merkel D. (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24: 547–561.
3. Cella D. Hackshaw M. Diaz J. Huang C. Deen K. Crescenzo R. (2013) Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study. J Clin Oncol 31(Suppl. 6): abstr. 346.
4. Cella D. Pickard A. Duh M. Guerin A. Mishagina N. Antras L. (2012) Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer 48: 311–323.
5. Cornelis N. Vermassen T. Schallier D. Machiels J. Gil T. Debruyne P. (2014) Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium. Acta Clin Belg 69: 335–340.
6. DaCosta Byfield S. McPheeters J. Burton T. Nagar S. Hackshaw M. (2015) Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis. J Manag Care Spec Pharm 21: 515–522.
7. Escudier B. Porta C. Bono P. Powles T. Eisen T. Sternberg C. (2014) Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 32: 1412–1418.
8. FACIT. (2015) Functional Assessment of Chronic Illness Therapy. Available at: http://www.facit.org (accessed August 2015).
9. Galvis V. Chow S. Lawrence D. Hawkins R. (2013) Clinical practice outcomes of patients treated with pazopanib for metastatic renal cell cancer (mRCC) – 6 year experience at a referral centre in Manchester, UK. Eur J Cancer 49(Suppl. 2): abstr. 2763.
10. Germone A. (2014) Experience with pazopanib in the treatment of metastatic renal cell carcinoma: a monocentric experience. Tumori 100: e165–e168.
11. GlaxoSmithKline. (2014) USA Product Information Pazopanib. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/ucm303649.htm (accessed August 2015).
12. Hackshaw M. Nagar S. Parks D. Miller L. (2014) Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Spec Pharm 20: 603–610.
13. Harnett J. MacLean E. Bhattacharyya H. Cisar L. Hoang C. Mardekian J. (2015) Sunitinib and pazopanib treatment patterns and cost outcomes in Medicare supplemental-covered patients with renal cell carcinoma. J Clin Oncol 33(Suppl. 7): abstr. 485.
14. Hirsch B. Harrison M. George D. Walker M. Chen C. Korytowsky B. (2014) Use of “real-world” data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. Med Oncol 31: 156.
15. Lai J. Beaumont J. Diaz J. Khan S. Cella D. (2015) Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer. Epub ahead of print 12 October 2015. DOI: 10.1002/cncr.29655.
16. Matrana M. Duran C. Shetty A. Xiao L. Atkinson B. Corn P. (2013a) Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49: 3169–3175.
17. Matrana M. Shetty A. Teegavarapu P. Kalra S. Xiao L. Atkinson B. (2013b) Outcomes of unselected patients with metastatic renal cell carcinoma treated with front-line pazopanib therapy. Eur J Cancer 49(Suppl. 2): abstr. 2779.
18. Mitchell C. Parikh O. (2014) Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib. Patient Prefer Adherence 8: 503–511.
19. Mohamed A. Hauber A. Neary M. (2011) Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics 29: 977–988.
20. Motzer R. Hutson T. Cella D. Reeves J. Hawkins R. Guo J. (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369: 722–731.
21. Motzer R. Hutson T. McCann L. Deen K. Choueiri T. (2014) Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370: 1769–1770.
22. National Cancer Institute. (2014) Surveillance, epidemiology, and end results program. In: National Comprehensive Cancer Network (ed.), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Kidney Cancer v1.2015. Bethesda, MD: National Cancer Institute, Surveillance Systems Branch.
23. National Comprehensive Cancer Network (2015) In: NCCN clinical practice guidelines in oncology (NCCN Guidelines®) Kidney Cancer. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
24. Novartis Europharm Limited. (2015) Pazopanib European SPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdf (accessed August 2015).
25. Novartis Pharmaceuticals Australia Pty Limited. (2015) Pazopanib Product Information Australia. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07077-3&d=2015080316114622412 (accessed August 2015).
26. Perez J. Pal S. Signorovitch J. Reichmann W. Li N. Liu Z. (2015) Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US: a comparison of retrospective chart reviews conducted in 2012 and 2014. J Clin Oncol 33(Suppl. 6): abstr. 15620.
27. Pick A. Nystrom K. (2012) Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther 34: 511–520.
28. Rao D. Butt Z. Rosenbloom S. Robinson D. Jr Von Roenn J. Kuzel T. (2009) A comparison of the renal cell carcinoma-symptom index (RCC-SI) and the functional assessment of cancer therapy-kidney symptom index (FKSI). J Pain Symptom Manage 38: 291–298.
29. Ricotta R. Di Bella S. (2014) Outcomes of patients with metastatic renal cell carcinoma treated with pazopanib in daily clinical practice: a single institution experience. Tumori 100: e87–e91.
30. Sanchez A. Domínguez R. De Velasco G. Pinto A. Puente J. Rubio G. (2013) Pazopanib in metastatic renal carcinoma (mRC): experience of 31 centers in Spain in first, second, third, or subsequent lines in daily clinical practice. J Clin Oncol 31(Suppl.): abstr. 15609.
31. Santoni M. Conti A. Porta C. Procopio G. Sternberg C. Basso U. (2015) Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol 193: 41–47.
32. Schmidinger M. Bojic M. Vogl U. Klinger C. Kramer G. Zielinski C. (2012) Safety and efficacy of pazopanib in heavily pretreated and treatment-naive patients with metastatic renal cell carcinoma (mRCC): a single center experience of the Medical University of Vienna, Austria. J Clin Oncol 30(Suppl.): abstr. 15090.
33. Sternberg C. Davis I. Deen K. Sigal E. Hawkins R. (2014) An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Oncology 87: 342–350.
34. Sternberg C. Davis I. Mardiak J. Szczylik C. Lee E. Wagstaff J. (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061–1068.
35. Sternberg C. Hawkins R. Wagstaff J. Salman P. Mardiak J. Barrios C. (2013) A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49: 1287–1296.
36. Tan J. Heilbrun L. Fontana J. Smith D. Heath E. Baranowski K. (2012) Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 20(Suppl. 5): abstr. 415.
37. Trask P. Tellefsen C. Espindle D. Getter C. Hsu M. (2008) Psychometric validation of the cancer therapy satisfaction questionnaire. Value Health 11: 669–679.
38. Vogelzang N. Hackshaw M. Hutson T. Bhowmik D. Yap M. Rembert D. (2015) First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US community oncology setting. Clin Genitourin Cancer 13: 210–217.
39. Wong M. Mohamed A. Hauber A. Yang J. Liu Z. Rogerio J. (2012) Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ 15: 1139–1148.
40. Yick D. Stukalin I. Wells C. Donskov F. Rini B. Lee J. (2015) Third-line therapy in metastatic renal cell carcinoma (mRCC): results from the International mRCC Database Consortium (IMDC). J Clin Oncol 33(Suppl. 6): abstr. e15578.